Myelodysplastic Syndromes (MDS) News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Onconova Presents Data on Rigosertib in Myelodysplastic Syndromes (MDS) at the ASH 2017 Meeting - GlobeNewswire (press release)



Onconova Presents Data on Rigosertib in Myelodysplastic Syndromes (MDS) at the ASH 2017 Meeting 
GlobeNewswire (press release)
NEWTOWN, Pa., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, delivered two poster presentations ...

and more » 


Actinium Pharmaceuticals Unveils Actimab-MDS and Planned Phase 2 Trial in Myelodysplastic Syndromes Targeted at ... - Nasdaq



Actinium Pharmaceuticals Unveils Actimab-MDS and Planned Phase 2 Trial in Myelodysplastic Syndromes Targeted at ... 
Nasdaq
05, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for safer myeloablation and ...

and more » 


Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at ... - Business Wire (press release)



Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at ... 
Business Wire (press release)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced preliminary results from the ...

and more » 


Syros tanks on single-digit response rate in AML, MDS trial - FierceBiotech



FierceBiotech
 
Syros tanks on single-digit response rate in AML, MDS trial 
FierceBiotech
Cambridge, Massachusetts-based Syros led on the fact that investigators saw ?clinical activity? in 43% of the acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients enrolled in the study. But, to the detriment of Syros' stock price ...
Syros Pursues Combination Development for Lead Candidate after Phase II Miss Genetic Engineering & Biotechnology News
Here's Why Syros Pharmaceuticals Got Crushed Today Nasdaq
5 Keys To Understanding Syros Pharma's ASH Presentation Benzinga
Seeking Alpha  -StreetInsider.com  -Endpoints News 
all 50 news articles » 


Acceleron's (XLRN) Acceleron ASH 2017 Update Conference (Transcript) - Seeking Alpha



Acceleron's (XLRN) Acceleron ASH 2017 Update Conference (Transcript) 
Seeking Alpha
The press release announcing our updated results from the ongoing Phase 2 clinical trials of Luspatercept in Myelodysplastic Syndromes, in addition to the presentation for today's webcast, are available on the investors and media page, and the ASH ...

 


Myelodysplastic Syndrome (MDS) Therapeutics Market is Trending Worldwide due to Trend's, Analysis & Forecast 2022 - MilTech



Myelodysplastic Syndrome (MDS) Therapeutics Market is Trending Worldwide due to Trend's, Analysis & Forecast 2022 
MilTech
Myelodysplastic Syndrome (MDS) Therapeutics market research and analysis report focus on rising market drifts to assist businesses find market opportunities and develop effective ways to optimise their market positions. Myelodysplastic Syndrome (MDS ...
How Social Media Can Help People With Cancer Curetoday.com

all 2 news articles » 


Health-Related Quality of Life Differs by Disease-Risk Category in MDS - Journal of Clinical Pathways



Journal of Clinical Pathways
 
Health-Related Quality of Life Differs by Disease-Risk Category in MDS 
Journal of Clinical Pathways
The relationship between transfusion dependency and health-related quality of life (HRQOL) in patients with myelodysplastic syndromes (MDS) may differ based on disease risk at diagnosis, according to research presented at the 59th American Society of ...

 


Onconova Therapeutics Announces Publication of Results from Phase 1/2 Study of Rigosertib in Patients with ... - GlobeNewswire (press release)



Onconova Therapeutics Announces Publication of Results from Phase 1/2 Study of Rigosertib in Patients with ... 
GlobeNewswire (press release)
NEWTOWN, Pa., Nov. 15, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer, with a primary focus on ...

and more » 


Dana-Farber/Brigham and Women's physician wins prestigious recognition from ASH - EurekAlert (press release)



Technology Networks
 
Dana-Farber/Brigham and Women's physician wins prestigious recognition from ASH 
EurekAlert (press release)
Ebert is notable for his leadership in describing the genomic landscape of adult myelodysplastic syndromes (MDS), including identifying critical new roles for ribosomal dysfunction. Specifically, he identified RPS14 as a key gene for deletion 5q MDS ...
Agent Reverses Resistance to Targeted Drug in Some Leukemias Technology Networks

all 3 news articles » 


Elderly Patients Significantly Underrepresented in Hematology Clinical Trials - Curetoday.com



Curetoday.com
 
Elderly Patients Significantly Underrepresented in Hematology Clinical Trials 
Curetoday.com
In total, 45 percent (19,908) of patients were enrolled in lymphoma trials; 24 percent (10,465) in chronic myeloid leukemia (CML) trials; 22 percent (9,605) in multiple myeloma (MM) trials; 2 percent (1,052) in acute myeloid leukemia (AML) or ...

and more »